Literature DB >> 1117893

Glucose tolerance and insulin secretion in patients with parathyroid disorders. Effect of serum calcium on insulin release.

K Yasuda, Y Hurukawa, M Okuyama, M Kikuchi, K Yoshinaga.   

Abstract

To evaluate the role of serum calcium in human insulin secretion, insulin responses after a 100-g oral glucose load were studied in nine patients with primary hyperparathyroidism, five with idiopathic hypoparathyroidism, three with pseudohypoparathyroidism and one with normocalcemic secondary hyperparathyroidism. Glucose tolerance values in these disorders were almost normal. Insulin responses in primary hyperparathyroidism were increased, and those in idiopathic hypoparathyroidism and pseudohypoparathyroidism were reduced significantly as compared to normal subjects. Isulin response in secondary hyperparathyroidism was normal. The calculated insulin area during an oral glucose load was significantly correlated with serum calcium (5.1 to 12.2 mg per deciliter), and a linear relation was obtained (y = 1.59x - 3.3, r = 0.81, p less than 0.001), although a relation with the glucose area was not found. These observations indicate that serum calcium has an important effect on insulin secretion in parathyroid disorders.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1117893     DOI: 10.1056/NEJM197503062921003

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  28 in total

1.  Glucose intolerance and primary hyperparathyroidism: an unresolved relationship.

Authors:  Mishaela R Rubin; Shonni J Silverberg
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

2.  Evaluation of glucose tolerance, insulin secretion, and insulin action in patients with primary hyperparathyroidism before and after surgery.

Authors:  R Prager; G Schernthaner; B Niederle; R Roka
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

Review 3.  Yogurt and Cardiometabolic Diseases: A Critical Review of Potential Mechanisms.

Authors:  Melissa Anne Fernandez; Shirin Panahi; Noémie Daniel; Angelo Tremblay; André Marette
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

Review 4.  The pathophysiology and clinical aspects of hypercalcemic disorders.

Authors:  D B Lee; E T Zawada; C R Kleeman
Journal:  West J Med       Date:  1978-10

5.  Potentiation of glibenclamide-induced insulin release by calcium infusion.

Authors:  L Gero; E Baranyi; K Steczek; G Petrányi; G Tamás
Journal:  Diabetologia       Date:  1977-08       Impact factor: 10.122

6.  Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism.

Authors:  F Tassone; L Gianotti; C Baffoni; F Cesario; G Magro; M Pellegrino; I Emmolo; M Maccario; G Borretta
Journal:  J Endocrinol Invest       Date:  2011-12-21       Impact factor: 4.256

7.  Target cells for 1,25 dihydroxyvitamin D3 in the pancreas.

Authors:  S A Clark; W E Stumpf; M Sar; H F DeLuca; Y Tanaka
Journal:  Cell Tissue Res       Date:  1980       Impact factor: 5.249

Review 8.  Vitamin D and diabetes.

Authors:  Joanna Mitri; Anastassios G Pittas
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

9.  Primary hyperparathyroidism is associated with decreased insulin receptor binding and glucose intolerance.

Authors:  R Prager; G Schernthaner; J Kovarik; G Cichini; K Klaushofer; R Willvonseder
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

Review 10.  Derangement of glucose metabolism in hyperparathyroidism.

Authors:  M Procopio; G Borretta
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.